<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">CoActive Communications</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:b9ef34de-6744-4bb4-ad9d-cb4720fc786f;id=18023</id> <rights type="text">Copyright 2018, CoActive Communications</rights> <updated>2018-05-16T16:03:00Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/gPxFg4wspjC5vC2ntLP16w==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/gPxFg4wspjC5vC2ntLP16w==" /> <entry> <id>https://www.globenewswire.com/news-release/2018/05/16/1507602/0/en/Non-Profit-Martial-Arts-Studio-Doubles-Space-Increases-Classes-and-Introduces-Karate-Inspired-Summer-Day-Camps-for-Kids.html</id> <title type="text">Non-Profit Martial Arts Studio Doubles Space, Increases Classes and Introduces Karate-Inspired Summer Day Camps for Kids</title> <published>2018-05-16T16:03:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2018/05/16/1507602/0/en/Non-Profit-Martial-Arts-Studio-Doubles-Space-Increases-Classes-and-Introduces-Karate-Inspired-Summer-Day-Camps-for-Kids.html" /> <content type="html"><![CDATA[Quantum Martial Arts Philosophy to “Leave No Child Behind” Thrives in San Francisco; the USA’s Most Expensive City <pre>Quantum Martial Arts Philosophy to “Leave No Child Behind” Thrives in San Francisco; the USA’s Most Expensive City</pre>]]></content> <dc:identifier>1507602</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>CoActive Communications</dc:contributor> <dc:modified>Wed, 16 May 2018 16:03 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://resource.globenewswire.com/Resource/Download/09244a95-8719-46a5-97a2-8f6b31b47c6b"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2018/05/16/1507602/0/en/Non-Profit-Martial-Arts-Studio-Doubles-Space-Increases-Classes-and-Introduces-Karate-Inspired-Summer-Day-Camps-for-Kids.html"> <img src="https://resource.globenewswire.com/Resource/Download/09244a95-8719-46a5-97a2-8f6b31b47c6b" width="600" align="left" border="0" alt="QMA circle image" title="At the end of each class, during closing circle, children review core values with their instructor, ask questions and have fun!" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Company Announcement</dc:subject> <dc:keyword>Tae Kwon Do</dc:keyword> <dc:keyword>Martial Arts</dc:keyword> <dc:keyword>Non-profit</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/07/24/1256431/0/en/SpeeDx-Eyes-Clear-Path-toward-Marketing-Antibiotic-Resistance-and-Detection-Tests-in-US-Market.html</id> <title type="text">SpeeDx Eyes Clear Path toward Marketing Antibiotic Resistance and Detection Tests in US Market </title> <published>2017-07-24T13:35:25Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/07/24/1256431/0/en/SpeeDx-Eyes-Clear-Path-toward-Marketing-Antibiotic-Resistance-and-Detection-Tests-in-US-Market.html" /> <content type="html"><![CDATA[<p><em><p>On-track for De Novo submission after successful meeting with the FDA</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Jul 24, 2017) -  SpeeDx Pty. Ltd., a developer of multiplex molecular diagnostic solutions, is moving forward with their plans for a De Novo submission of their <strong>Resistance</strong>Plus™ MG test after initial favorable feedback from the FDA. The test will potentially be a first-to-market product in the US, providing detection of the emerging sexually transmitted infection <em>Mycoplasma genitalium </em>(MG) along with genetic markers that confer high level resistance to azithromycin, a common first-line antibiotic treatment.</p>]]></content> <dc:identifier>1256431</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/06/08/1256429/0/en/SpeeDx-and-Cepheid-Announce-European-Distribution-Partnership.html</id> <title type="text">SpeeDx and Cepheid Announce European Distribution Partnership </title> <published>2017-06-08T12:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/06/08/1256429/0/en/SpeeDx-and-Cepheid-Announce-European-Distribution-Partnership.html" /> <content type="html"><![CDATA[<p><em><p>Strategic commercial partnership in key European markets</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Jun 8, 2017) - SpeeDx Pty, Ltd., a developer of innovative molecular diagnostic solutions, today announced an agreement with Cepheid for distribution of its PlexPCR™ and ResistancePlus™ molecular diagnostic products in key markets throughout Europe. The agreement, covering Germany, France, Italy, and the UK, will increase coverage for the market-leading ResistancePlus MG test, the first CE-IVD test for the sexually transmitted infection (STI) <em>Mycoplasma genitalium</em> (MG) to combine detection with testing for azithromycin resistance. </p>]]></content> <dc:identifier>1256429</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="http://media.marketwire.com/attachments/201706/MOD-103192_SpeeDx_ResistancePlus_MG-min.jpg"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2017/06/08/1256429/0/en/SpeeDx-and-Cepheid-Announce-European-Distribution-Partnership.html"> <img src="http://media.marketwire.com/attachments/201706/MOD-103192_SpeeDx_ResistancePlus_MG-min.jpg" width="600" align="left" border="0" alt="Photo" title="SpeeDx ResistancePlus MG test" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/04/24/1256426/0/en/SpeeDx-and-Thermo-Fisher-Scientific-Announce-Strategic-Partnership-for-FDA-Clearance-of-Molecular-Diagnostic.html</id> <title type="text">SpeeDx and Thermo Fisher Scientific Announce Strategic Partnership for FDA Clearance of Molecular Diagnostic </title> <published>2017-04-24T12:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/04/24/1256426/0/en/SpeeDx-and-Thermo-Fisher-Scientific-Announce-Strategic-Partnership-for-FDA-Clearance-of-Molecular-Diagnostic.html" /> <content type="html"><![CDATA[<p><em><p>ResistancePlus(TM) MG Test would bring disease and antibiotic resistance testing to U.S. market for sexually transmitted infection and potential "superbug"</p></em></p><p>SYDNEY, AUSTRALIA and SOUTH SAN FRANCISCO, CA--(Marketwired - Apr 24, 2017) - SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has signed an agreement with Thermo Fisher Scientific, the world leader in serving science, in support of SpeeDx's plan to submit its ResistancePlus™ MG Test for clearance by the U.S. Food & Drug Administration (FDA). </p>]]></content> <dc:identifier>1256426</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/02/13/1256424/0/en/Review-published-in-Nature-Reviews-Urology-advises-antibiotic-resistance-testing-for-M-genitalium-sexually-transmitted-infection-and-potential-superbug-SpeeDx-ResistancePlus-TM-MG-.html</id> <title type="text">Review published in Nature Reviews Urology advises antibiotic resistance testing for M. genitalium sexually transmitted infection and potential "superbug"; SpeeDx ResistancePlus(TM) MG Test only CE-marked commercial test available for this purpose </title> <published>2017-02-13T14:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/02/13/1256424/0/en/Review-published-in-Nature-Reviews-Urology-advises-antibiotic-resistance-testing-for-M-genitalium-sexually-transmitted-infection-and-potential-superbug-SpeeDx-ResistancePlus-TM-MG-.html" /> <content type="html"><![CDATA[<p>SYDNEY, AUSTRALIA--(Marketwired - Feb 13, 2017) - SpeeDx Pty. Ltd. today announced that the authors of the review, <em>Antimicrobial-resistant sexually transmitted infections: gonorrhoea and </em>Mycoplasma genitalium, published in <em>Nature Reviews Urology</em> <a rel="nofollow" href="http://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2016.268.html" title="">http://www.nature.com/nrurol/journal/vaop/ncurrent/full/nrurol.2016.268.html</a>, recommended that appropriate <em>M. genitalium</em> diagnostic testing become available on a routine basis in clinical practice and should ideally be supplemented with molecular detection for antibiotic resistance. Currently, SpeeDx has the only commercially available test capable of simultaneously detecting the sexually transmitted infection (STI) <em>M. genitalium</em> and antibiotic resistance status. SpeeDx ResistancePlus™ MG test is CE marked for sale in Europe and TGA approved for sale in Australia. SpeeDx plans to seek a de novo clearance for the test with the U.S. Food and Drug Administration this year.</p>]]></content> <dc:identifier>1256424</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/16/1256420/0/en/SpeeDx-and-UgenTec-launch-FastFinder-for-ResistancePlus-MG-Test.html</id> <title type="text">SpeeDx and UgenTec launch FastFinder for ResistancePlus MG Test </title> <published>2017-01-16T15:03:46Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/16/1256420/0/en/SpeeDx-and-UgenTec-launch-FastFinder-for-ResistancePlus-MG-Test.html" /> <content type="html"><![CDATA[<p><em><p>Artificially intelligent interpretation module automatically incorporates test results into lab information systems</p></em></p><p>SYDNEY, AUSTRALIA and HASSELT, BELGIUM--(Marketwired - Jan 16, 2017) - <strong> </strong>SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, and UgenTec NV, a bioinformatics company that develops artificially intelligent PCR interpretation software, today announced the launch of a smart interpretation module for the <a rel="nofollow" href="http://www.speedx.com.au/resistanceplus-mg/?utm_source=ResistancePlusMG&utm_medium=hyperlinks" title="ResistancePlus™ MG">ResistancePlus™ MG</a> test for <em>M. genitalium</em>, a rapidly growing sexually transmitted infection (STI) that has developed significant resistance to first-line antibiotic treatment. </p>]]></content> <dc:identifier>1256420</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2017/01/09/1256418/0/en/Evaluation-of-SpeeDx-s-CE-marked-ResistancePlus-TM-MG-test-for-M-genitalium-published-in-Journal-of-Clinical-Microbiology.html</id> <title type="text">Evaluation of SpeeDx's CE-marked ResistancePlus(TM) MG test for M. genitalium published in Journal of Clinical Microbiology </title> <published>2017-01-09T14:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2017/01/09/1256418/0/en/Evaluation-of-SpeeDx-s-CE-marked-ResistancePlus-TM-MG-test-for-M-genitalium-published-in-Journal-of-Clinical-Microbiology.html" /> <content type="html"><![CDATA[<p><em><p>ResistancePlus(TM) MG rapidly and reliably detects the disease and determines antibiotic resistance of this increasingly resistant sexually transmitted infection</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Jan 9, 2017) - SpeeDx Pty. Ltd. announced that the study, <em>Evaluation of a commercial multiplex PCR assay for simultaneous detection of </em>Mycoplasma genitalium <em>and macrolide resistance-associated mutations in clinical specimens</em>, by Chloe� Le Roy, Nadège He�nin, Ce�cile Be�bear and Sabine Pereyre has been accepted for publication by the <em>Journal of Clinical Microbiology</em>. <a rel="nofollow" href="http://jcm.asm.org/content/early/recent" title="">http://jcm.asm.org/content/early/recent</a></p>]]></content> <dc:identifier>1256418</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty. Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/09/19/1256416/0/en/SpeeDx-Receives-CE-IVD-Mark-for-ResistancePlus-TM-MG.html</id> <title type="text">SpeeDx Receives CE-IVD Mark for ResistancePlus(TM) MG </title> <published>2016-09-19T12:05:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/09/19/1256416/0/en/SpeeDx-Receives-CE-IVD-Mark-for-ResistancePlus-TM-MG.html" /> <content type="html"><![CDATA[<p><em><p>New Molecular Assay Is Only Commercial Test to Detect Both M. genitalium and Antibiotic Resistance for One of the World's Fastest Spreading Sexually Transmitted Diseases</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Sep 19, 2016) - SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus™ MG assay that detects both the sexually transmitted disease (STD) <em>Mycoplasma genitalium</em> (often referred to as <em>M. genitalium </em>or MG) and mutations in the 23S rRNA gene of the bacteria that have been shown to confer resistance to azithromycin, a commonly prescribed macrolide-based antibiotic.</p>]]></content> <dc:identifier>1256416</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/06/29/1256414/0/en/SpeeDx-Receives-CE-IVD-Mark-for-PlexPCR-TM-HSV-1-2-VZV.html</id> <title type="text">SpeeDx Receives CE-IVD Mark for PlexPCR(TM) HSV-1&2, VZV </title> <published>2016-06-29T13:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/06/29/1256414/0/en/SpeeDx-Receives-CE-IVD-Mark-for-PlexPCR-TM-HSV-1-2-VZV.html" /> <content type="html"><![CDATA[<p><em><p>A Simple Multiplexed Solution for Herpes Viral Detection</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Jun 29, 2016) - SpeeDx Pty., Ltd. announced today it has received CE-IVD marking for its PlexPCR™ HSV-1&2, VZV multiplex qPCR kit. The new multiplex molecular diagnostic test offers a single-well solution to cover the detection and differentiation of three herpes viruses (HSV-1, HSV-2, VZV) in addition to an internal control. Validated for use on multiple lesion specimen types, the test is designed to streamline herpes testing workflows and support appropriate clinical and therapeutic management for infections that present similarly.</p>]]></content> <dc:identifier>1256414</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty., Ltd. </dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/06/02/1256413/0/en/SpeeDx-Establishes-New-European-Subsidiary.html</id> <title type="text">SpeeDx Establishes New European Subsidiary </title> <published>2016-06-02T17:36:37Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/06/02/1256413/0/en/SpeeDx-Establishes-New-European-Subsidiary.html" /> <content type="html"><![CDATA[<p><em><p>Headquarters Based in the London Bioscience Innovation Centre</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Jun 2, 2016) - SpeeDx Pty. Ltd. announced today the establishment of a European subsidiary company, SpeeDx Limited, to be headquartered in the London Bioscience Innovation Centre. The UK-based headquarters will support the future launch of SpeeDx PlexPCR™ multiplex qPCR assays. SpeeDx has filed for CE-IVD Mark for PlexPCR™ HSV-1&2, VZV for the detection of three different types of herpes viruses and is finalising test submission for <em>Mycoplasma genitalium</em>, a newly-recognized sexually transmitted infection.</p>]]></content> <dc:identifier>1256413</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty, Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/04/08/1256411/0/en/SpeeDx-to-Feature-PlexPCR-TM-and-ResistancePlus-TM-Tests-on-M-genitalium-at-ECCMID.html</id> <title type="text">SpeeDx to Feature PlexPCR(TM) and ResistancePlus(TM) Tests on M. genitalium at ECCMID </title> <published>2016-04-08T17:17:17Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/04/08/1256411/0/en/SpeeDx-to-Feature-PlexPCR-TM-and-ResistancePlus-TM-Tests-on-M-genitalium-at-ECCMID.html" /> <content type="html"><![CDATA[<p><em><p>Posters and Conference Session to Highlight Multiplex Detection of Antibiotic Resistance</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Apr 8, 2016) - SpeeDx Pty, Ltd. today announced that it will feature its PlexPCR™ for detection of infectious disease pathogens and the unique ResistancePlus™ multiplex qPCR test for detection of M. genitalium and antimicrobial resistance markers<sup>1</sup> at the ECCMID 2016 Congress in Amsterdam, the Netherlands, 9-12 April 2016. More information will be available at Booth 103.</p>]]></content> <dc:identifier>1256411</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty, Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/04/04/1256407/0/en/SpeeDx-Announces-Distribution-Agreement-for-PlexPCR-TM-and-ResistancePlus-TM-Molecular-Diagnostics-Products-With-Goffin-Molecular-Technologies.html</id> <title type="text">SpeeDx Announces Distribution Agreement for PlexPCR(TM) and ResistancePlus(TM) Molecular Diagnostics Products With Goffin Molecular Technologies </title> <published>2016-04-04T13:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/04/04/1256407/0/en/SpeeDx-Announces-Distribution-Agreement-for-PlexPCR-TM-and-ResistancePlus-TM-Molecular-Diagnostics-Products-With-Goffin-Molecular-Technologies.html" /> <content type="html"><![CDATA[<p><em><p>Goffin's Distribution Channels Will Allow Broader Availability and Accessibility of SpeeDx Diagnostics in the Benelux Markets</p></em></p><p>SYDNEY, AUSTRALIA--(Marketwired - Apr 4, 2016) - SpeeDx Pty, Ltd. today announced a distribution agreement with Goffin Molecular Technologies B.V., a molecular diagnostic company based in the Netherlands. The agreement will open new channels for SpeeDx' PlexPCR™ and unique ResistancePlus™ multiplex real time polymerase chain reaction (qPCR) product lines to the Benelux market (Belgium, Netherlands and Luxembourg). </p>]]></content> <dc:identifier>1256407</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>SpeeDx Pty, Ltd.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2016/02/22/1256404/0/en/Retrotope-Advances-RT001-in-Clinical-Trials-to-Treat-Friedreich-s-ataxia.html</id> <title type="text">Retrotope Advances RT001 in Clinical Trials to Treat Friedreich's ataxia </title> <published>2016-02-22T14:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2016/02/22/1256404/0/en/Retrotope-Advances-RT001-in-Clinical-Trials-to-Treat-Friedreich-s-ataxia.html" /> <content type="html"><![CDATA[<p><em><p>Announces Open Enrollment of Highest Dose Cohort</p></em></p><p>LOS ALTOS, CA--(Marketwired - Feb 22, 2016) - Retrotope, a privately held clinical stage pharmaceutical company, today announced the successful completion of the first dose cohort and the opening of patient enrollment for the highest dose cohort in its ongoing 28-day study of orally dosed RT001 in Friedreich's ataxia (FA) patients. RT001 was well tolerated and no serious adverse events or dose limiting toxicities were observed.</p>]]></content> <dc:identifier>1256404</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Retrotope</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2015/11/12/1256401/0/en/e-Vision-Accelerates-Development-Program-for-First-Fully-Tunable-Electronic-Contact-Lens.html</id> <title type="text">e-Vision Accelerates Development Program for First Fully Tunable Electronic Contact Lens </title> <published>2015-11-12T19:05:46Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2015/11/12/1256401/0/en/e-Vision-Accelerates-Development-Program-for-First-Fully-Tunable-Electronic-Contact-Lens.html" /> <content type="html"><![CDATA[<p><em><p>New Patent, Funding and Commercial Partnerships to Deliver Only Contact Lens Allowing Continuously Adjustable Focus</p></em></p><p>LAS VEGAS, NV--(Marketwired - Nov 12, 2015) - E-Vision Smart Optics, Inc., a Sarasota-based company specializing in electrically-modulated tunable lens technology, announced today that it is developing the first electronic contact lens (ECL) that will allow the wearer to continuously adjust far, near and middle-vision customized to the individual's own needs. </p>]]></content> <dc:identifier>1256401</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>e-Vision</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> </entry> <entry> <id>https://www.globenewswire.com/news-release/2012/11/13/1256519/0/en/Transcend-Medical-Announces-12-Month-European-Study-Results-of-the-CyPass-Micro-Stent-R-at-AAO-2012.html</id> <title type="text">Transcend Medical Announces 12-Month European Study Results of the CyPass Micro-Stent(R) at AAO 2012 </title> <published>2012-11-13T18:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2012/11/13/1256519/0/en/Transcend-Medical-Announces-12-Month-European-Study-Results-of-the-CyPass-Micro-Stent-R-at-AAO-2012.html" /> <content type="html"><![CDATA[<p><em><p>Micro-Invasive Stent Implanted During Phaco-Cataract Surgery Achieves Sustained IOP Lowering Effect in Glaucomatous Eyes at 12 Months</p></em></p><p>CHICAGO, IL--(Marketwire - Nov 13, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the 12-month results of the European multicenter CyPass Clinical Experience (CyCLE) study, a clinical trial designed to evaluate the long-term safety, effectiveness and clinical experience of the CyPass Micro-Stent<sup>®</sup>. The outcomes were presented today by Steven D. Vold, MD of Vold Vision (Fayettevile, Arkansas) during the 2012 American Academy of Ophthalmology Annual Meeting in Chicago.</p>]]></content> <dc:identifier>1256519</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Transcend Medical</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>glaucoma</dc:keyword> <dc:keyword>eyesight</dc:keyword> <dc:keyword>MIGS</dc:keyword> <dc:keyword>suprachoroidal</dc:keyword> <dc:keyword>ASCRS</dc:keyword> <dc:keyword>American Society of Cataract and Refractive Surgery</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2012/11/12/1256517/0/en/Transcend-Medical-Launches-the-Transcend-Vold-Gonio-Lens-TVG-for-Improved-Visualization-During-Micro-Invasive-Glaucoma-Surgery.html</id> <title type="text">Transcend Medical Launches the Transcend Vold Gonio Lens (TVG) for Improved Visualization During Micro-Invasive Glaucoma Surgery </title> <published>2012-11-12T14:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2012/11/12/1256517/0/en/Transcend-Medical-Launches-the-Transcend-Vold-Gonio-Lens-TVG-for-Improved-Visualization-During-Micro-Invasive-Glaucoma-Surgery.html" /> <content type="html"><![CDATA[<p><em><p>TVG Allows Physicians to Gently Stabilize Eye Movement and to Reduce Scope Tilt During Micro-Invasive Glaucoma Surgery</p></em></p><p>CHICAGO, IL--(Marketwire - Nov 12, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, today announced the commercial availability of the Transcend Vold Gonio Lens (TVG). The new lens is specifically designed to improve visualization and surgical control of the eye during micro-invasive glaucoma surgery (MIGS) procedures, a growing class of less-invasive surgical glaucoma treatments.</p>]]></content> <dc:identifier>1256517</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Transcend Medical</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>glaucoma</dc:keyword> <dc:keyword>eyesight</dc:keyword> <dc:keyword>MIGS</dc:keyword> <dc:keyword>suprachoroidal</dc:keyword> <dc:keyword>ASCRS</dc:keyword> <dc:keyword>American Society of Cataract and Refractive Surgery</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2012/04/21/1256515/0/en/Transcend-Medical-Announces-Four-Scientific-Abstracts-at-the-American-Society-of-Cataract-and-Refractive-Surgery-Annual-Meeting.html</id> <title type="text">Transcend Medical Announces Four Scientific Abstracts at the American Society of Cataract and Refractive Surgery Annual Meeting </title> <published>2012-04-21T13:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2012/04/21/1256515/0/en/Transcend-Medical-Announces-Four-Scientific-Abstracts-at-the-American-Society-of-Cataract-and-Refractive-Surgery-Annual-Meeting.html" /> <content type="html"><![CDATA[<p><em><p>12-Month Results of the CyPass Micro-Stent(R) Glaucoma Treatment to Be Presented</p></em></p><p>CHICAGO, IL--(Marketwire - Apr 21, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced that the CyPass Micro-Stent<sup>®</sup> will be the subject of four clinical presentations this week at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting.</p>]]></content> <dc:identifier>1256515</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Transcend Medical</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>glaucoma</dc:keyword> <dc:keyword>eyesight</dc:keyword> <dc:keyword>MIGS</dc:keyword> <dc:keyword>suprachoroidal</dc:keyword> <dc:keyword>ASCRS</dc:keyword> <dc:keyword>American Society of Cataract and Refractive Surgery</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2011/11/07/1256513/0/en/Sunshine-Heart-Announces-Results-of-Its-C-Pulse-R-Feasibility-Trial-at-the-Transcatheter-Cardiovascular-Therapeutics-Conference.html</id> <title type="text">Sunshine Heart Announces Results of Its C-Pulse(R) Feasibility Trial at the Transcatheter Cardiovascular Therapeutics Conference </title> <published>2011-11-07T13:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2011/11/07/1256513/0/en/Sunshine-Heart-Announces-Results-of-Its-C-Pulse-R-Feasibility-Trial-at-the-Transcatheter-Cardiovascular-Therapeutics-Conference.html" /> <content type="html"><![CDATA[<p><em><p>Patients Implanted With the C-Pulse Heart Assist System Demonstrated Statistically Significant Improvement Based on New York Heart Association Class Reduction, Quality of Life and Left Ventricular Ejection Fraction</p></em></p><p>SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Nov 7, 2011) - <strong> </strong>Sunshine Heart, Inc. (<exchange name="ASX">ASX</exchange>: <ticker name="SHC">SHC</ticker>), a global medical device company focused on innovative technologies for moderate to severe heart failure, today announced the results of the approved U.S. Food and Drug Administration (FDA) feasibility clinical trial with the C-Pulse System. </p>]]></content> <dc:identifier>1256513</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sunshine Heart, Inc.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>moderate heart failure</dc:keyword> <dc:keyword>LVAD</dc:keyword> <dc:keyword>C-Pulse Heart Assist System</dc:keyword> <dc:keyword>balloon counterpulsation</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2011/10/19/1256510/0/en/Sunshine-Heart-s-Feasibility-Trial-Outcomes-to-Be-Presented-at-Transcatheter-Cardiovascular-Therapeutics-Conference.html</id> <title type="text">Sunshine Heart's Feasibility Trial Outcomes to Be Presented at Transcatheter Cardiovascular Therapeutics Conference </title> <published>2011-10-19T09:00:00Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2011/10/19/1256510/0/en/Sunshine-Heart-s-Feasibility-Trial-Outcomes-to-Be-Presented-at-Transcatheter-Cardiovascular-Therapeutics-Conference.html" /> <content type="html"><![CDATA[<p><em><p>Six-Month Follow-Up Results for Patients Enrolled in the C-Pulse(R) Heart Assist System Clinical Study to Be Released</p></em></p><p>SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Oct 19, 2011) - Sunshine Heart, Inc. (<exchange name="ASX">ASX</exchange>: <ticker name="SHC">SHC</ticker>), a global medical device company focused on innovative technologies for moderate heart failure, today announced that the C-Pulse Heart Assist System will be featured in two clinical presentations at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The TCT symposium, sponsored by the Cardiovascular Research Foundation, will take place November 7 through 11 in San Francisco, California.</p>]]></content> <dc:identifier>1256510</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sunshine Heart, Inc.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>moderate heart failure</dc:keyword> <dc:keyword>LVAD</dc:keyword> <dc:keyword>C-Pulse Heart Assist System</dc:keyword> <dc:keyword>balloon counterpulsation</dc:keyword> </entry> <entry> <id>https://www.globenewswire.com/news-release/2011/08/03/1256508/0/en/Sunshine-Heart-Appoints-New-US-Board-Member.html</id> <title type="text">Sunshine Heart Appoints New US Board Member </title> <published>2011-08-03T19:19:15Z</published> <updated>2024-11-25T05:27:29Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2011/08/03/1256508/0/en/Sunshine-Heart-Appoints-New-US-Board-Member.html" /> <content type="html"><![CDATA[<p><em><p>Gregory Waller's US Financial Management and Governance Experience to Support Growth Initiatives</p></em></p><p>SYDNEY, AUSTRALIA and EDEN PRAIRIE, MN--(Marketwire - Aug 3, 2011) - Sunshine Heart, Inc. (<exchange name="ASX">ASX</exchange>: <ticker name="SHC">SHC</ticker>), a global medical device company focused on innovative technologies for moderate heart failure, today announced the appointment of Gregory Waller as an independent non-executive director. Mr. Waller brings more than 30 years of financial management and industry experience to Sunshine Heart with an established history of serving on the boards of several successful medical device companies. He is the second US-based board member to be appointed this year following the appointment of Paul Buckman in January.</p>]]></content> <dc:identifier>1256508</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Sunshine Heart, Inc.</dc:contributor> <dc:modified>Wed, 13 Dec 2017 03:54 GMT</dc:modified> <dc:keyword>moderate heart failure</dc:keyword> <dc:keyword>LVAD</dc:keyword> <dc:keyword>C-Pulse Heart Assist System</dc:keyword> <dc:keyword>balloon counterpulsation</dc:keyword> </entry> </feed>